Medtronic plc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD from Q1 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Medtronic plc quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and growth rate from Q1 2016 to Q2 2024.
  • Medtronic plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending July 26, 2024 was $1.31B, a 2.09% decline year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $1.31B -$28M -2.09% Jul 26, 2024 10-Q 2024-08-27
Q1 2024 $1.28B -$259M -16.8% Apr 26, 2024 10-Q 2024-08-27
Q4 2023 $1.62B -$2.9B -64.1% Jan 26, 2024 10-Q 2024-02-27
Q3 2023 $1.31B -$3.52B -72.8% Oct 27, 2023 10-Q 2023-11-30
Q2 2023 $1.34B -$801M -37.4% Jul 28, 2023 10-Q 2024-08-27
Q1 2023 $1.54B -$2.17B -58.5% Apr 28, 2023 10-Q 2024-08-27
Q4 2022 $4.52B +$1.04B +30% Jan 27, 2023 10-Q 2024-02-27
Q3 2022 $4.83B +$1.93B +66.5% Oct 28, 2022 10-Q 2023-11-30
Q2 2022 $2.14B -$864M -28.8% Jul 29, 2022 10-Q 2023-08-31
Q1 2022 $3.71B +$121M +3.37% Apr 29, 2022 10-K 2024-06-20
Q4 2021 $3.48B -$1.6B -31.5% Jan 28, 2022 10-Q 2023-03-01
Q3 2021 $2.9B -$3.52B -54.8% Oct 29, 2021 10-Q 2022-12-01
Q2 2021 $3B -$3.5B -53.8% Jul 30, 2021 10-Q 2022-09-01
Q1 2021 $3.59B -$547M -13.2% Apr 30, 2021 10-K 2024-06-20
Q4 2020 $5.08B +$1.37B +36.9% Jan 29, 2021 10-Q 2022-03-03
Q3 2020 $6.42B +$2.46B +62% Oct 30, 2020 10-Q 2021-12-02
Q2 2020 $6.5B +$1.42B +27.9% Jul 31, 2020 10-Q 2021-09-02
Q1 2020 $4.14B -$253M -5.76% Apr 24, 2020 10-K 2023-06-22
Q4 2019 $3.71B +$6M +0.16% Jan 24, 2020 10-Q 2021-03-05
Q3 2019 $3.96B +$51M +1.3% Oct 25, 2019 10-Q 2020-12-03
Q2 2019 $5.08B Jul 26, 2019 10-Q 2020-09-03
Q1 2019 $4.39B +$724M +19.7% Apr 26, 2019 10-K 2022-06-23
Q4 2018 $3.7B Jan 25, 2019 10-Q 2020-02-28
Q3 2018 $3.91B Oct 26, 2018 10-Q 2019-12-03
Q1 2018 $3.67B -$1.3B -26.1% Apr 27, 2018 10-K 2021-06-25
Q1 2017 $4.97B +$2.09B +72.7% Apr 28, 2017 10-K 2020-06-19
Q1 2016 $2.88B Apr 29, 2016 10-K 2019-06-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.